Search

Bridgebio Pharma Inc

Open

SectorGezondheidszorg

82.75 0.28

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

81.25

Max

82.81

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+29.92% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

16B

Vorige openingsprijs

82.47

Vorige sluitingsprijs

82.75

Nieuwssentiment

By Acuity

50%

50%

144 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 jul 2026, 23:56 UTC

Correlated Moves
News

American Water Works Company Inc. is trading lower in after-market hours amid geopolitical tensions and rising crude oil prices impacting market sentiment.

22 jul 2026, 23:56 UTC

News

Wynn Resorts received approval to expand its Wynn Palace resort in Macau, including a new hotel and entertainment center. Shares showed little change in after-market trading.

22 jul 2026, 23:51 UTC

News

Rollins Inc shares fell after second-quarter results missed expectations. Adjusted EPS was $0.32, below the consensus estimate of $0.34, amid slowing growth.

22 jul 2026, 23:51 UTC

Social Media
News

CSX Corp reported second-quarter revenue of $3.94 billion and EPS of $0.54, exceeding expectations, leading to higher shares in after-market trading.

22 jul 2026, 23:51 UTC

Social Media
News

Joby Aviation will release its Q2 2026 results on August 5, generating positive investor sentiment. Shares are trading higher in after-market hours.

22 jul 2026, 23:51 UTC

Social Media
News

Southwest Airlines reported second-quarter earnings above estimates but missed on revenue, leading to shares trading lower in after-market hours.

22 jul 2026, 23:51 UTC

News

Norfolk Southern Corp shares are trading lower in after-market hours following Union Pacific and Canadian National Railway's agreement that may impact its competitive position.

22 jul 2026, 23:51 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I is lower in after-market hours amid concerns over rising crude oil prices and geopolitical tensions affecting market sentiment.

22 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Amazon.com Inc is under Senate investigation for alleged Chinese influence on its marketplace, contributing to a decline in investor sentiment and stock price after hours.

22 jul 2026, 23:51 UTC

ETF Constituents
News
Macro News

Vanguard Information Technology ETF is higher in after-market hours, driven by positive sentiment ahead of earnings from major tech firms and strong performances from key holdings.

22 jul 2026, 23:46 UTC

News

EQT Corporation's stock rose after it raised full-year natural gas production guidance and secured long-term supply agreements, despite lower-than-expected earnings.

22 jul 2026, 23:46 UTC

Social Media
News

Intel explores a partnership with SK Hynix for its Ohio facility. Shares are trading higher after securing Fortinet as its first external foundry customer.

22 jul 2026, 23:46 UTC

Social Media
News

Crown Castle reported second-quarter adjusted FFO of $1.13, exceeding estimates. Shares are higher in after-market trading following the results and strategic business sale.

22 jul 2026, 23:41 UTC

News

Goosehead Insurance shares rise in after-market hours following strong Q2 results, with revenue of $113.4 million and a leadership transition announcement.

22 jul 2026, 23:41 UTC

News

Community Health Systems reported a significant decline in net income and lowered its full-year EPS guidance, leading shares to trade lower in after-market hours.

22 jul 2026, 23:41 UTC

Social Media
News

Kinder Morgan's Q2 earnings of $0.37 per share exceeded estimates, driving shares higher in after-market trading. Revenue rose to $4.48 billion, surpassing expectations.

22 jul 2026, 23:36 UTC

Social Media
Correlated Moves
News

Shutterstock shares are lower in after-market hours following the suspension of dividends and the resignation of Chief Accounting Officer Steven Ciardiello.

22 jul 2026, 23:36 UTC

Correlated Moves
News

Microsoft shares are lower in after-market hours amid a securities class action lawsuit regarding its Copilot products and concerns over capital expenditures ahead of earnings.

22 jul 2026, 23:36 UTC

Social Media
News

Rocket Lab shares are lower in after-market hours, reflecting broader sector trends. The company will release second-quarter 2026 results on August 10, 2026.

22 jul 2026, 23:31 UTC

Social Media
News

Leslie's Inc shares declined in after-hours trading amid reports of a potential Chapter 11 bankruptcy, raising concerns about the company's financial stability.

22 jul 2026, 23:26 UTC

News

Synopsys Inc will report third-quarter results on August 26, 2026, after market close. Shares are trading higher in after-market hours.

22 jul 2026, 23:22 UTC

Social Media
News

Tesla Inc. shares declined in after-hours trading following a Q2 earnings miss, with adjusted EPS at $0.33 against expectations of $0.51.

22 jul 2026, 23:22 UTC

Social Media
News

Medpace Holdings Inc. reported Q2 revenue of $707.3 million, exceeding expectations, and raised 2026 guidance, driving shares higher in after-market trading.

22 jul 2026, 23:16 UTC

News

Hims & Hers Health shares declined to about $31.66 after mixed options sentiment, with calls outpacing puts amid lighter trading volume.

22 jul 2026, 23:16 UTC

News

Interactive Brokers reported second-quarter net revenue growth of 28% to $1.90 billion, driven by a 67% increase in customer margin loans.

22 jul 2026, 23:11 UTC

Social Media
News

Lockheed Martin announced a quarterly dividend of $3.45 per share, boosting investor sentiment. Shares are higher in after-market trading following the announcement.

22 jul 2026, 23:06 UTC

News

Constellation Energy Corp shares are lower in after-market trading, influenced by geopolitical tensions and concerns over potential oil supply disruptions.

22 jul 2026, 23:06 UTC

News

Dollar Tree shares are lower in after-market trading amid scrutiny over new price scanners and rising costs, prompting concerns about customer loyalty.

22 jul 2026, 23:06 UTC

News

General Motors raised its 2026 profit outlook to $14 billion to $16 billion, boosting shares higher in after-market hours following strong EBIT performance.

22 jul 2026, 23:02 UTC

Social Media
News

QuantumScape Corp's shares declined in after-market hours following a narrower loss and lowered capital expenditures guidance amid concerns over future cash flow.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

29.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  29.92%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

144 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat